Metagenomi Therapeutics, Inc. business relationships
Companies named in Metagenomi Therapeutics, Inc.’s 10-K filed 2026-03-05, and public companies whose annual reports name Metagenomi Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 12 / 100 Top 2% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Metagenomi Therapeutics, Inc.’s annual report 7
“In November 2022, we received an $80.0 million upfront payment from Ionis for the Wave 1 drug discovery research collaboration and selected Target 1.” SEC filing
“Collaboration and License Agreement by and between the Registrant and Ionis Pharmaceuticals, Inc., dated November 10, 2022” SEC filing
“On April 26, 2024 (the "Termination Date"), we and ModernaTx, Inc. ("Moderna") mutually terminated the Strategic Collaboration and License Agreement, dated October 29, 2021 (the "Moderna Agreement"), by and between us and Moderna.” SEC filing
“We are currently in Wave 1 of our collaboration with Ionis Pharmaceuticals, Inc. ("Ionis") focused on four disease targets in cardiometabolic indications.” SEC filing
“Pursuant to the terms of the Moderna Agreement, the Company and Moderna collaborated on the research and development of in vivo genome editing therapies directed at certain targets and the commercialization of such genome editing therapies.” SEC filing
“Without sufficient funding, our license agreements, such as our Non-Exclusive License Agreement with Acuitas Therapeutics, Inc., and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under such agreements.” SEC filing
“On September 30, 2025 (the "Termination Date"), we delivered to Affini-T Therapeutics, Inc. ("Affini-T") a notice to terminate the Development, Option and License Agreement, dated June 14, 2022 (the "Affini-T Agreement") by and between us and Affini-T, effective immediately, due to Affini-T's making...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.